Showing results (341-350 of 369) with videos related to

Sort By:
Pageof 37
Journal of Internal Medicine|October 14, 2017
What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?O Ringdén, M Labopin, B Sadeghi, et al.
Leukemia|June 8, 2011
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groupsF Damm, F Thol, I Hollink, et al.
Annals of Hematology|May 25, 2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemiaW K Hofmann, G Heil, C Zander, et al.
Bone Marrow Transplantation|December 24, 2013
Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trialM Koenigsmann, J Casper, C Kahl, et al.
Blood|June 14, 2000
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT)R E Champlin, N Schmitz, M M Horowitz, et al.
Leukemia|August 10, 2011
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemiaF Damm, T Bunke, F Thol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†S P Robinson, A Boumendil, H Finel, et al.
Leukemia|April 12, 2016
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarateA Chaturvedi, M M Araujo Cruz, N Jyotsana, et al.
Bone Marrow Transplantation|September 4, 2003
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myelomaH Einsele, M Bamberg, W Budach, et al.
Annals of Hematology|October 6, 1998
Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy appliedT Fischer, A Neubauer, J Mohm, et al.
Pageof 37